Inclusion Criteria:~* Age 45-85~* Diagnosis of mild to moderate AD~* Clinical laboratory values within normal
range or < 1.5 times ULN~* If receiving AD-specific treatment, have been on stable dose for â‰¥ 3 months prior to
first dose of study drug.~* Life expectancy of >2 years~* Able and willing to provide written informed consent~
